Mallinckrodt PLC lost its bet to pay lower Medicaid rebates for Acthar Gel (repository corticotropin injection) by claiming the US Food and Drug Administration's approval of a new indication made it a new drug product.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?